Manager
Release time:
2020-08-14
said that there is a company that has set up an internal magazine in order to build a corporate culture. The company called on employees to actively contribute, but few employees participated. For this reason, the company decided to include the contribution as part of the work, and the division of labor among various departments was quantitative. As a result, various responses and reasons for shirk were drawn out. Some people went online to "learn from" and even made a hasty job. After a period of time, some departments have reduced their quotas from five to three per month, and then to one, but they still cannot complete the task. Even if there is a task assessment, the work cannot be carried out. The leader of
company had a brainwave and changed the amount of tasks assigned to the department to the voluntary "want" index of each department. he could report as much as he could, and each manuscript would be rewarded with a certain amount of cash. the more manuscripts, the greater the reward. if he did not participate, there would be no reward.
This trick is quite clever. Once implemented, a large number of "poets" and "writers" have sprung up like bamboo shoots after a spring rain. It turned out that all kinds of excuses were quickly turned into "we can do it", "we want it" and "we want it". In the past, departments that could not finish one article per month could also exceed the quota, and they kept on raising the target. At that time, the number of submissions rose and the content of the manuscripts was rich and colorful.
After half a year like this, the number of contributions from each department has stabilized, showing their true strength. The leader was very happy and held a meeting. First, he praised and then re-determined the contribution indicators for each department according to the contribution situation in the past six months. A department that could not finish one article in January successfully received a monthly target of 10 articles. Then the leaders announced a new contribution system. For those who exceed the target, each article will be rewarded with a number. If the target is not met, each article will be assessed with a number.
As soon as the new system came out, the crowd was in an uproar, and then they accepted it convincingly, which made the leaders very gratified. Since then, the company's internal magazine has been doing well. (Yan Mei)
Tutor Comments (Xu Shuifa, member of Zhejiang Writers Association, writer of short stories):
Sometimes the reason why short stories cannot be written well is that the difference between short stories and stories cannot be distinguished. In fact, the two are obviously different. The short novel is written by people, and all the plots are only set to help shape the characters. In other words, the plot in the short novel is tailored for the characters. On the contrary, the characters in the story follow the development of the story. In this article, no matter the leaders and contributors, their words and deeds are to make corresponding responses and introduce corresponding measures to make up for or implement with the completion of the reporting task. This is essentially a story. If the full text sets up a person in charge of enterprise newspapers and periodicals, how to make his subordinates complete the task and complete the character image of an enterprise management cadre who uses wisdom to do a good job, it is also a good short novel.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page